NEW YORK, Nov. 9 (GenomeWeb News) - Shares in CombiMatrix were down 5.9 percent, or $.12, at $1.91 in mid-afternoon trading after gaining 5.1 percent yesterday on news that it was part of an alliance aimed at monitoring vaccine production.
As GenomeWeb News reported yesterday, CombiMatrix and Novavax plan to develop a technique monitoring vaccine production. Traditional flu-vaccine development and production is too slow to accommodate rapidly evolving flu strains, the company said. CombiMatrix's technique improves the process by tracking the genetic fidelity of the genes encoding the vaccine.
CombiMatrix and Novavax will test the method's efficacy on Novavax's VLP process for producing H5N1 bird flu vaccine.
Financial details were not disclosed.